Sensus Healthcare, Inc.

NASDAQ:SRTS

Medical - Devices

Healthcare
$3.22 +3.05%

+$0.09 today

Market cap
$53.01M
Beta
1.09
P/E (TTM)
-6.5
EPS (TTM)
-$0.47
52W Low $2.66High $5.92

Volume 0.08M

Average 0.06M

SRTS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Sensus Healthcare, Inc.NASDAQ: SRTS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development dips below year-ago levels

Q1 FY2026 research & development of $1.59M fell 39.0% year over year, behind the +14.7% change in trailing-twelve-month research & development. Sequentially, it fell 15.5% from the prior quarter. Over 3 fiscal years it compounded at +31.0% a year.

Context

  • Research & development amounted to 28.3% of revenue in FY2025, up 18.2 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -39.0% toward the trailing-twelve-month pace of +14.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.59M-15.5% QoQ
Last fiscal yearDec 2025
$7.78M+84.5% YoY
LTMMar 2026
$6.76M+14.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-39.0%——
1 year+84.5%——
3-year CAGR+31.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
7.78M USD
Year-over-year change
+84.5%
4-year CAGR
+22.7%

Research & Development vs competitors

How SRTS compares with its peers on the latest reported figures

  • SRTS's LTM Mar 2026 research & development of $6.76M is the lowest of the 6 companies compared; the peer median is $20.13M.
  • Its year-over-year change of +14.7% is the 2nd highest of 6, against a peer median of -12.3%.
  • Research & development amounts to 30.0% of revenue for SRTS, versus a peer median of 62.5%.
SRTS Competitors Peer median
Research & Development for SRTS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KPTIKaryopharm Therapeutics Inc.LTM Mar 2026$124.78M -12.3%-5.5%82.6%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$83.18M -24.7%-0.5%—
BDMDBaird Medical Investment Holdings LimitedFY2025$20.13M +226.0%+73.4%89.3%
TELATELA Bio, Inc.LTM Jun 2026$9.54M +8.0%+1.0%11.9%
MDAISpectral AI, Inc.LTM Mar 2026$7.09M -63.2%—42.4%
SRTSSensus Healthcare, Inc.LTM Mar 2026$6.76M +14.7%+31.0%30.0%
Peer median (excluding SRTS) $20.13M-12.3%+0.3%62.5%

Competitors are the stored peer set for SRTS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.04M44.53M24.41M41.81M27.48M
Cost of Revenue10.05M14.9M10.35M17.38M15.62M
Gross Profit16.99M29.63M14.06M24.43M11.87M
Gross Margin62.8%66.5%57.6%58.4%43.2%
Research & Development3.44M3.46M3.68M4.22M7.78M
Selling, General & Admin9.43M11.34M10.76M12.13M14.4M
Operating Expenses12.87M14.8M14.44M16.34M22.17M
Depreciation & Amortization613K509K461K432K386K
EBITDA4.73M28.5M1.11M9.45M(9.24M)
EBITDA Margin17.5%64.0%4.6%22.6%-33.6%
Operating Income4.12M14.83M(382K)8.09M(10.31M)
Operating Margin15.2%33.3%-1.6%19.4%-37.5%
Interest Income2K382K992K932K683K
Interest Expense1K2K000
Other Income / Expenses(1K)13.16M1.03M932K683K
Income Before Tax4.12M27.99M652K9.02M(9.62M)
Pre-Tax Margin15.2%62.9%2.7%21.6%-35.0%
Income Tax Expense03.75M167K2.38M(1.91M)
Net Income4.12M24.24M485K6.65M(7.72M)
Net Margin15.2%54.4%2.0%15.9%-28.1%
EPS (Basic)0.251.470.030.41(0.47)
EPS (Diluted)0.251.460.030.41(0.47)
Weighted Avg Shares16.48M16.48M16.26M16.31M16.33M
Weighted Avg Shares (Diluted)16.5M16.62M16.27M16.36M16.33M

Sensus Healthcare, Inc.

NASDAQ:SRTS

Intrinsic Alpha fair value

Locked

Current Price

$3.22

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.